Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: October 2016 (Specifically referencing events on October 13, 2016)
Business Focus: Biopharmaceutical development, specifically the Phase II study of CF102 for non-alcoholic fatty liver disease (NAFLD).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements.
Material Changes
Clinical Development Update: On October 13, 2016, the company submitted the clinical trial protocol for its Phase II study of CF102 to a leading Institutional Review Board (IRB) in Israel. The study targets the treatment of non-alcoholic fatty liver disease (NAFLD), which is the precursor to non-alcoholic steatohepatitis (NASH).
Guidance, Outlook, and Risks
Outlook: The submission of the protocol indicates progression toward initiating the Phase II clinical trial for CF102.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the inherent uncertainties of clinical trial approvals and execution. The document incorporates a press release by reference but does not reproduce specific risk factors within the text provided.
Investor Verification Checklist
- Verify the approval status of the Phase II protocol by the Israeli Institutional Review Board.
- Review the attached Exhibit 99.1 (Press Release dated October 13, 2016) for detailed study design and timeline expectations.
- Monitor subsequent filings for the official start date of the Phase II clinical trial.
- Check the company's most recent Form 20-F for updated financial position and cash runway, as this 6-K contains no financial data.